Plan De Preparación Para La Pandemia De Influenza

Objectives

Provide a global and national framework for managing possible or actual influenza pandemics, recognising that spread may not be preventable but that advance preparation can reduce illness, deaths, disruption, secondary disasters and public panic.[1][2]The framework distinguishes complementary World Health Organization (WHO) and national responsibilities, while requiring adaptable contingency planning because pandemic emergence, severity and transmission patterns are unpredictable.[1][3][4]

• Establish and maintain preparedness across inter-pandemic, alert, pandemic, post-wave and recovery phases, from detection of a novel influenza subtype through return to normal inter-pandemic activity.[5][6][7][8]
• Assess the risk posed by new influenza viruses, including whether human infection, sustained person-to-person transmission and severe disease have been confirmed.[9][10][2]
• Reduce transmission and impact through surveillance, case management, vaccination, antiviral policy, pharmaceutical logistics, public communication and other national control measures.[11][6][7]
• Develop and distribute safe, effective pandemic vaccines equitably, while strengthening seed-virus preparation, potency testing, regulatory processes, production capacity and emergency distribution arrangements.[6][12][13][14][15]
• Prepare for animal-human influenza risks, including reassortment between human and animal viruses, direct animal-to-human transmission and possible emergence from unknown reservoirs.[16][17][18]
• Establish permanent National Committees for Pandemic Planning to lead routine preparedness, develop scenario-based contingency plans and coordinate action when WHO confirms a novel virus with human-transmission potential.[19][20]

Priority national action areas include governance, surveillance, laboratory diagnosis, scientific and medical coordination, vaccination, antiviral and antibiotic supplies, logistics, legal and economic arrangements, communications, social services and emergency response.[11][20][21]Preparedness should account for complications that increase hospitalisation and mortality, especially among older people, young children, pregnant women and people with chronic disease.[22]

Implementation

Implementation combines WHO-led international assessment and coordination with nationally led preparedness and response. WHO announces preparedness and pandemic phases following international consultation, while national health authorities activate and adapt predetermined plans to the characteristics of the virus, local capacity and vaccine availability.[9][6][7]The approach relies on continuous surveillance, laboratory confirmation, multidisciplinary governance, flexible resource reallocation and communication with health professionals and the public.[23][3][24]

• Maintain a Pandemic Task Force during inter-pandemic periods to assess reports of novel viruses and initiate appropriate measures.[25]
• Operate international surveillance through WHO, National Influenza Laboratories and WHO Collaborating Centres in Atlanta, London, Melbourne and Tokyo, supported by reporting through Flunet, the Weekly Epidemiological Record and direct communications to national authorities.[25][5]
• Strengthen laboratory capacity to isolate, identify, sequence and compare viruses; test antiviral susceptibility; investigate exposures and contacts; and transfer selected isolates to collaborating centres under appropriate biocontainment conditions.[5][9][10]
• Increase surveillance and special investigations in affected countries, use case definitions for early spread, and extend regional and international monitoring beyond the usual influenza season where required.[26]
• Coordinate national planning through a clear chain of command, current contact lists, alternate members, alert and escalation procedures, and continuous review of national pandemic plans.[20]
• Include or consult public-health, regulatory, laboratory, clinical, veterinary, pharmaceutical, social-service, emergency, voluntary, telecommunications, media, occupational-health, ethics and community representatives.[19][20]
• Coordinate neighbouring-country and regional plans through exchanges of national strategies, WHO-supported regional meetings and international consultation on cross-border issues and unequal vaccine availability.[20][27][24]

Vaccine preparedness requires early preparation of seed strains, reagents and clinical-trial capacity.[10][13]The approach includes use of high-growth reassortant seed viruses where strains grow poorly in eggs, consideration of tissue-culture or recombinant technologies, centralised licensing arrangements, advance contract provisions and flexible packaging to extend supply or support two-dose schedules.[28][29][14]A centrally financed clearing house may pool procurement, balance supply and demand, and support humanitarian donations for designated high-risk groups in countries with insufficient resources.[14]

National plans should determine vaccination strategy early, prepare mass-vaccination sites, procure vaccines, antivirals, antibiotics and protective materials, and establish storage, transport, licensing and emergency-finance arrangements.[20][21][30]They should also plan antiviral access before vaccine availability, prioritise critical groups such as exposed health teams and laboratory workers, and monitor antiviral safety and resistance.[31][32]

Monitoring should use surveillance of consultations, laboratory diagnoses, pneumonia admissions, mortality, absence where appropriate, vaccine and medicine stocks, distribution and use.[33]WHO should monitor global spread and impact, update technical guidance, estimate vaccine and antiviral needs during later waves, assess overall pandemic impact and revise its plan after the event.[6][8]The source does not specify a unified quantitative indicator set, reporting timetable, accountability sanctions or monetary budget; it instead calls for approximate national response budgets, identification of infrastructure gaps and resource mobilisation for countries with limited capacity.[19][20][27]

Monitoring & Evaluation

The framework centres on continuous surveillance, laboratory confirmation, phased risk assessment and international reporting to detect novel influenza viruses, determine whether sustained human-to-human transmission is occurring, guide pandemic-phase declarations and review response measures.[11][23][25][5][9][10][6]

• Maintain inter-pandemic surveillance through national health authorities, National Influenza Laboratories, the World Health Organization (WHO) Collaborating Centres and the Pandemic Task Force, with review of reported novel viruses and comparative analysis of selected isolates.[25][5]
• Confirm and characterise potential pandemic viruses by excluding laboratory error, investigating exposures and contacts, re-isolating viruses, sequencing genes, testing antiviral susceptibility and assessing clinical complications and antibody responses.[9][10]
• Define surveillance case definitions and monitor influenza consultations, laboratory diagnoses, pneumonia admissions, mortality, school or workplace absence, and impacts by age, occupation and medical risk where nationally determined.[26][33]
• Assess progression through preparedness phases using evidence of person-to-person transmission, secondary cases, sustained outbreaks and the relative importance of emerging variants, supported by international consultation before a pandemic declaration.[25][5][10]
• Strengthen reporting through electronic communications, WHO’s Flunet reporting system, the Weekly Epidemiological Record, submissions from national laboratories and orderly dissemination of situation reports and technical guidance.[23][25][5]
• Monitor global spread, disease impact, vaccine needs, antiviral availability and the likelihood of secondary waves, which may occur within three to nine months of the first epidemic wave.[6][7][8]
• Evaluate vaccine candidates through pre-clinical and clinical trials, potency and batch standardisation, vaccine-safety reporting, adverse-event surveillance, and monitoring of vaccine supply and utilisation in real time or near real time.[10][28][15]
• Monitor antiviral safety and resistance, including the potential emergence and transmission of resistant variants during treatment.[32]
• Require national health authorities to report periodically to WHO on National Committees for Pandemic Planning and provide copies of national pandemic plans.[19]
• Review response measures continuously through governmental and non-governmental expert groups, assess overall pandemic impact after the event, document lessons and update the influenza pandemic plan.[8][3][24]

Quantitative performance indicators, standard reporting timetables, evaluation protocols, accountability sanctions and budget-monitoring arrangements are generally not specified; several operational surveillance measures and reporting responsibilities are instead left to national policy decisions.[19][27][33][34][13][14]

Costing & Financing

The framework recognises that a severe pandemic could overwhelm health services and economies, requiring advance budgeting, rapid resource reallocation, international assistance and planning for pharmaceutical, laboratory, logistics and workforce constraints, but it provides no quantified overall budget or funding gap.[1][20][3][24]

• Prepare approximate budgets for selected pandemic responses and contingency scenarios, including differing attack rates, while taking available resources into account when deciding vaccination strategies.[20]
• Estimate costs for vaccines, antiviral drugs, antibiotics, protective materials, auxiliary equipment, storage, transport, enhanced surveillance, control measures and other alternative response options.[21][30]
• Identify shortages in infrastructure, laboratory equipment, health workers, healthcare facilities and pharmaceutical distribution, and use planning to support research, pre-pandemic improvements and external assistance.[20][27]
• Mobilise resources for countries with limited capacity through partnerships with UNICEF, the International Federation of Red Cross and Red Crescent Societies, the World Bank, international aid agencies and other humanitarian organisations.[7][21]
• Redirect resources rapidly from other activities when a credible pandemic threat requires an intensified response.[3][24]
• Recognise that many countries lack sufficient preparedness resources and that maintaining enough anti-influenza medicines to treat whole populations globally is unrealistic.[2]
• Finance a central clearing house through contributions from cooperating countries to pool vaccine procurement, balance supply and demand, and support humanitarian donations for designated high-risk groups in resource-constrained countries.[14]
• Account for variations in vaccine cost per dose according to whether governments provide vaccines without charge or recipients purchase them directly.[14]
• Recognise that extensive antiviral prophylaxis is constrained by cost and supply, while maintaining medicines for critical needs such as health teams and laboratory workers exposed to the new virus.[15][31]

No monetary allocations, vaccine prices, dedicated financing mechanisms, quantified funding gaps, currencies or economic assumptions are specified, apart from the requirement to prepare indicative or approximate budgets and assess response costs.[20][21][30][14]